ADDvise Group AB (publ) is a Swedish company focused on providing equipment and services for healthcare and research facilities. Established in 1989 and headquartered in Stockholm, Sweden, ADDvise operates through two primary business units: 1. **Lab**: This unit offers comprehensive research environments and customized laboratory solutions, including laboratory furniture, protective ventilation systems, climate-controlled clean rooms, and various laboratory equipment. 2. **Healthcare**: This segment develops and supplies medical technology products, such as medical devices, consumables, and pharmaceuticals, targeting areas like urology, gynecology, emergency care, and surgery. The company consists of over 20 subsidiaries and reported annual revenues of nearly SEK 1.6 billion in 2025. As of that year, ADDvise employed approximately 615 individuals. In December 2025, Amplex AB, a significant shareholder, offered to acquire ADDvise Group AB at SEK 1.65 per B-share, valuing the company at over SEK 1 billion. This offer was accepted by Fredrik Celsing, the CEO of Amplex and Chairman of ADDvise's board, while other board members were still assessing the proposal. ADDvise Group AB is listed on the Nasdaq First North Premier Growth Market under the ticker symbol ADDV.B.
AI-researched from public web sources, not from the exchange listing itself — may contain errors or omissions and is not a substitute for verifying independently.
ADDvise Group AB (publ)'s offering is currently approved on OTHER. ADDvise Group AB (publ) is headquartered in Sweden. It is classified under Biotech.
Other IPOs DiscoverIPO tracks that share a sector, market, or underwriter with ADDvise Group AB (publ).
Drop a live deal card into your own site — works in WordPress, Ghost, Notion, Webflow, and any self-hosted page that allows an <iframe>. It does not work in Substack or in an emailed newsletter — no email client, and Substack itself, supports arbitrary iframes. For those, use the share image or the attribution text below instead.
<iframe src="https://www.discoveripo.com/embed/addvise-group-ab-publ" width="100%" height="300" style="border:0;max-width:560px" loading="lazy" title="ADDvise Group AB (publ) — DiscoverIPO"></iframe>
Dark by default. For a light background, use https://www.discoveripo.com/embed/addvise-group-ab-publ?theme=light as the src instead.
https://www.discoveripo.com/ipo/addvise-group-ab-publ/opengraph-image
ADDvise Group AB (publ) IPO details — tracked by DiscoverIPO: https://www.discoveripo.com/ipo/addvise-group-ab-publ?utm_source=embed&utm_medium=text&utm_campaign=addvise-group-ab-publ
Get emailed when ADDvise Group AB (publ)'s terms, price, or expected date change — no weekly noise, just this company.
ADDvise Group AB (publ) is listing on OTHER.
ADDvise Group AB (publ) is a Swedish company focused on providing equipment and services for healthcare and research facilities. Established in 1989 and headquartered in Stockholm, Sweden, ADDvise operates through two primary business units: 1. **Lab**: This unit offers comprehensive research environments and customized laboratory solutions, including laboratory furniture, protective ventilation systems, climate-controlled clean rooms, and various laboratory equipment. 2. **Healthcare**: This segment develops and supplies medical technology products, such as medical devices, consumables, and pharmaceuticals, targeting areas like urology, gynecology, emergency care, and surgery. The company consists of over 20 subsidiaries and reported annual revenues of nearly SEK 1.6 billion in 2025. As of that year, ADDvise employed approximately 615 individuals. In December 2025, Amplex AB, a significant shareholder, offered to acquire ADDvise Group AB at SEK 1.65 per B-share, valuing the company at over SEK 1 billion. This offer was accepted by Fredrik Celsing, the CEO of Amplex and Chairman of ADDvise's board, while other board members were still assessing the proposal. ADDvise Group AB is listed on the Nasdaq First North Premier Growth Market under the ticker symbol ADDV.B.
European Securities and Markets Authority's Prospectus Regulation register — a prospectus approval date, not a confirmed listing date. Retrieved Aug 26, 2026.
View the original filing on ESMA →Not investment advice. DiscoverIPO is an informational database. Nothing here is a recommendation to buy or sell any security, and no content should be relied on as financial advice. All figures come from public filings and exchange calendars, may be incomplete or out of date, and should be verified against the original source before you act on them.
We use analytics and marketing cookies to understand traffic and improve the site. Cookie Policy